Acquired and inherited amyloidosis: Knowledge driving patients' care

Laura Obici, David Adams

Research output: Contribution to journalReview articlepeer-review


Until recently, systemic amyloidoses were regarded as ineluctably disabling and life-threatening diseases. However, this field has witnessed major advances in the last decade, with significant improvements in therapeutic options and in the availability of accurate and non-invasive diagnostic tools. Outstanding progress includes unprecedented hematological response rates provided by risk-adapted regimens in light chain (AL) amyloidosis and the approval of innovative pharmacological agents for both hereditary and wild-type transthyretin amyloidosis (ATTR). Moreover, the incidence of secondary (AA) amyloidosis has continuously reduced, reflecting advances in therapeutics and overall management of several chronic inflammatory diseases. The identification and validation of novel therapeutic targets has grounded on a better knowledge of key molecular events underlying protein misfolding and aggregation and on the increasing availability of diagnostic, prognostic and predictive markers of organ damage and response to treatment. In this review, we focus on these recent advancements and discuss how they are translating into improved outcomes. Neurological involvement dominates the clinical picture in transthyretin and gelsolin inherited amyloidosis and has a significant impact on disease course and management in all patients. Neurologists, therefore, play a major role in improving patients' journey to diagnosis and in providing early access to treatment in order to prevent significant disability and extend survival.

Original languageEnglish
Pages (from-to)85-101
Number of pages17
JournalJournal of the Peripheral Nervous System
Issue number2
Publication statusPublished - Jun 1 2020


  • amyloidosis
  • cardiomyopathy
  • light chains
  • peripheral neuropathy
  • transthyretin

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Acquired and inherited amyloidosis: Knowledge driving patients' care'. Together they form a unique fingerprint.

Cite this